Technical Analysis for DCPH - Deciphera Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 26.61 5.81% 1.46
DCPH closed up 3.41 percent on Tuesday, January 15, 2019, on 69 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical DCPH trend table...

Date Alert Name Type % Chg
Jan 15 Calm After Storm Range Contraction 5.81%
Jan 15 Wide Bands Range Expansion 5.81%
Jan 15 Overbought Stochastic Strength 5.81%
Jan 14 Stochastic Sell Signal Bearish 9.42%
Jan 14 Calm After Storm Range Contraction 9.42%
Jan 14 Narrow Range Bar Range Contraction 9.42%
Jan 14 NR7 Range Contraction 9.42%
Jan 14 NR7-2 Range Contraction 9.42%
Jan 14 Wide Bands Range Expansion 9.42%
Jan 14 Overbought Stochastic Strength 9.42%

Older signals for DCPH ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Deciphera Pharmaceuticals, LLC is a United-States based clinical-stage biopharmaceutical company. The Company provides treatment for cancer patients. The Company focuses on developing tumor-targeted and immuno-targeted kinase inhibitors. Its switch control inhibitor platform is engaged in producing kinase inhibitors with distinct profiles and anti-cancer effects. Its tumor-targeting therapies include DCC-2618. DCC-2618 is a pan-KIT and PDGFR alpha kinase switch control inhibitor in clinical development for the treatment of KIT and/or Platelet-derived growth factor receptor alpha-driven cancers, including gastrointestinal stromal tumors, glioblastoma multiforme and systemic mastocytosis. Its Immuno-Targeted Therapies include DCC-3014 and Rebastinib. DCC-3014 is a potent and highly-selective immunokinase inhibitor targeting colony stimulating factor receptor 1 (CSF1R). Rebastinib is a TIE2 inhibitor targeting TIE2 expressing macrophages. Rebastinib is in the clinical development stage.
Is DCPH a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 45.61
52 Week Low 18.55
Average Volume 338,197
200-Day Moving Average 30.0016
50-Day Moving Average 23.3774
20-Day Moving Average 22.7445
10-Day Moving Average 23.964
Average True Range 1.7577
ADX 22.08
+DI 20.846
-DI 12.8821
Chandelier Exit (Long, 3 ATRs ) 21.8269
Chandelier Exit (Short, 3 ATRs ) 24.9631
Upper Bollinger Band 26.7471
Lower Bollinger Band 18.7419
Percent B (%b) 0.8
BandWidth 35.196201
MACD Line 0.2685
MACD Signal Line -0.164
MACD Histogram 0.4324
Fundamentals Value
Market Cap 802.91 Million
Num Shares 31.9 Million
EPS -16.03
Price-to-Earnings (P/E) Ratio -1.57
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 26.55
Resistance 3 (R3) 26.39 25.77 26.31
Resistance 2 (R2) 25.77 25.41 25.85 26.23
Resistance 1 (R1) 25.46 25.20 25.62 25.62 26.16
Pivot Point 24.84 24.84 24.92 24.92 24.84
Support 1 (S1) 24.53 24.48 24.69 24.69 24.14
Support 2 (S2) 23.91 24.27 23.99 24.07
Support 3 (S3) 23.60 23.91 23.99
Support 4 (S4) 23.76